SecBot SecBot
6-K ·Filed Nov 9, 2026

ARGX

ARGENX SE
BULLISH
Impact 6/10
Horizonmonths Processed7d 14h ago SEC0001104659-26-124180
Notable filing: 6-K
Actionable Insight ▲ Bullish

Watch for sBLA submission by end of 2026 and FDA acceptance/priority review. The DM cohort missed statistical significance, which may limit the DM label expansion path. Monitor upcoming ACR Convergence 2026 presentation on November 11 for additional detail.

DirectionBullish
Confidencehigh
Horizonmonths

efgartigimod

▲ Bullish Named in this 6-K
Impact
Phase
Approved (Phase 3 for pipeline expansion)
Time to market
Already FDA-approved and commercialized (December 2021 for gMG). Pipeline expansion into autoimmune myositis is in regulatory submission phase following positive Phase 3 data.
Next catalyst
None dated

What to watchWatch for argenx's regulatory filing for efgartigimod in autoimmune myositis following the positive Phase 3 ALKIVIA readout (Aug 17, 2026), that submission will unlock a PDUFA catalyst. Also track Vyvgart quarterly sales growth trajectory (60% YoY) as the key driver of earnings beats and estimate revisions.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$962.27
T+0 close · Nov 9, 2026 · via day close
Latest settled
−1.18%
T+5 · $950.95
Vs SPY
+0.52%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $962.27entry
  2. T+1 · 7d ago +0.96%α +1.33% · $971.55
  3. T+5 · 15h ago −1.18%α +0.52% · $950.95
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

argenx announced positive Phase 3 ALKIVIA data for efgartigimod in autoimmune myositis, meeting the primary endpoint in the combined IMNM and DM population with a statistically significant 15.4-point greater improvement in Total Improvement Score at Week 52 versus placebo. The company plans to submit an sBLA to the FDA for efgartigimod in IMNM by end of 2026, supported by Breakthrough Therapy Designation. This is a clinical data press release, not a periodic financial results release.

Key Facts

  • Phase 3 ALKIVIA met primary endpoint in combined IMNM and DM population: 15.4-point greater improvement in mean TIS at Week 52 vs placebo (p=0.0011; 48.0 vs 32.6).
  • IMNM patients showed 14.8-point greater improvement in mean TIS vs placebo (p=0.0048; 45.1 vs 30.2).
  • DM patients showed 14.5-point greater improvement in mean TIS vs placebo (p=0.1093; 51.5 vs 37.0), not statistically significant.
  • argenx plans to submit sBLA to FDA for efgartigimod in IMNM by end of 2026, supported by Breakthrough Therapy Designation.
  • Approximately 20,000 IMNM patients and 40,000 DM patients in the U.S. with no approved targeted therapies.
  • Safety profile consistent with prior studies.

Financial Impact

Potential label expansion into IMNM (20,000 U.S. patients, no approved therapies) and DM (40,000 U.S. patients) could significantly expand VYVGART Hytrulo's addressable market beyond current gMG and CIDP approvals.

revenue

Risk Factors

  • DM cohort did not reach statistical significance on the primary endpoint, which may complicate FDA approval for that indication.
  • Regulatory approval and commercial launch timelines are uncertain; sBLA submission by end of 2026 is a target, not a commitment.
  • Competition from other FcRn blockers and emerging therapies in autoimmune myositis could limit market share.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-124180
Document: tm2629301d1_6k.htm0001104659-26-124180
Document: 0001104659-26-124180-index-headers.html0001104659-26-124180
Document: 0001104659-26-124180-index.html0001104659-26-124180
Document: 0001104659-26-124180.txt0001104659-26-124180
Earnings Context (Synthetic; results releases only)0001104659-26-124180

Track record

23 reports on ARGX

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +30.22% at T+60 after the Jun 3, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 Viewing Entry $962.27 Now $950.95 −1.18% settles Dec 8
  2. Nov 9, 20267d ago 6-K Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $894.77 Now $950.95 +6.28% settles Dec 4
  5. Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $897.85 Now $950.95 +5.91% settles Nov 27
  6. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $875.76 Now $950.95 +8.59% settles Nov 19
  7. Oct 19, 202628d ago 6-K Bullish 7/10 Entry $825.61 to $950.95 Now $950.95 +15.18% ▲ +15.18% +18.64% vs SPY
  8. Oct 8, 20265w ago 6-K Mixed 6/10 Entry $818.63 to $931.38 Now $950.95 +16.16% ▲ +13.77% +19.06% vs SPY
  9. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $970.66 to $871.52 Now $950.95 −2.03% ▼ −10.21% −10.87% vs SPY
  10. Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $984.04 to $818.63 Now $950.95 −3.36% ▼ −16.81% −18.93% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (11h 25m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026